Ian Majewski

Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing

Luyi Tian, Jafar S Jabbari, Rachel Thijssen, Quentin Gouil, Shanika L Amarasinghe, Oliver Voogd, Hasaru Kariyawasam, Mei RM Du, Jakob Schuster, Changqing Wang, Shian Su, Xueyi Dong, Charity W Law, Alexis Lucattini, Yair David Joseph Prawer, Coralina Collar-Fernandez, Jin D Chung, Timur Naim, Audrey Chan, Chi Hai Ly, et al.

Journal article  |  2021  |  GENOME BIOLOGY

A modified Chromium 10x droplet-based protocol that subsamples cells for both short-read and long-read (nanopore) sequencing toget..

MINTIE: identifying novel structural and splice variants in transcriptomes using RNA-seq data

Marek Cmero, Breon Schmidt, Ian J Majewski, Paul G Ekert, Alicia Oshlack, Nadia M Davidson

Journal article  |  2021  |  GENOME BIOLOGY

Calling fusion genes from RNA-seq data is well established, but other transcriptional variants are difficult to detect using exist..

The crux of Cux1 in myeloid neoplasms Comment

Ian J Majewski

Journal article  |  2021  |  BLOOD

CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors

Zhen Xu, Cassandra J Vandenberg, Elizabeth Lieschke, Ladina Di Rago, Clare L Scott, Ian J Majewski

Journal article  |  2021  |  MOLECULAR CANCER RESEARCH

Patients with cancer treated with PARP inhibitors (PARPi) experience various side effects, with hematologic toxicity being most co..

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Rachel Thijssen, Sarah T Diepstraten, Donia Moujalled, Edward Chew, Christoffer Flensburg, Melissa X Shi, Michael A Dengler, Veronique Litalien, Sarah MacRaild, Maoshan Chen, Natasha S Anstee, Boris Reljic, Sarah S Gabriel, Tirta M Djajawi, Chris D Riffkin, Brandon J Aubrey, Catherine Chang, Lin Tai, Zhen Xu, Thomas Morley, et al.

Journal article  |  2021  |  BLOOD

Selective targeting of BCL-2 with the BH3-mimetic venetoclax has been a transformative treatment for patients with various leukemi..

Finding a suitable library size to call variants in RNA-Seq

Anna Quaglieri, Christoffer Flensburg, Terence P Speed, Ian J Majewski

Journal article  |  2020  |  BMC BIOINFORMATICS

BACKGROUND: RNA sequencing allows the study of both gene expression changes and transcribed mutations, providing a highly effectiv..

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

Chong Chyn Chua, Andrew W Roberts, John Reynolds, Chun Yew Fong, Stephen B Ting, Jessica M Salmon, Sarah MacRaild, Adam Ivey, Ing Soo Tiong, Shaun Fleming, Fiona C Brown, Sun Loo, Ian J Majewski, Stefan K Bohlander, Andrew H Wei

Journal article  |  2020  |  JOURNAL OF CLINICAL ONCOLOGY

PURPOSE: The B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has an emerging role in acute myeloid leukemia (AML), with promising r..

A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction

Joanne M Hildebrand, Maria Kauppi, Ian J Majewski, Zikou Liu, Allison J Cox, Sanae Miyake, Emma J Petrie, Michael A Silk, Zhixiu Li, Maria C Tanzer, Gabriela Brumatti, Samuel N Young, Cathrine Hall, Sarah E Garnish, Jason Corbin, Michael D Stutz, Ladina Di Rago, Pradnya Gangatirkar, Emma C Josefsson, Kristin Rigbye, et al.

Journal article  |  2020  |  NATURE COMMUNICATIONS

MLKL is the essential effector of necroptosis, a form of programmed lytic cell death. We have isolated a mouse strain with a singl..

MINTIE: identifying novel structural and splice variants in transcriptomes using RNA-seq data

Marek Cmero, Breon Schmidt, Ian Majewski, Paul Ekert, Alicia Oshlack, Nadia Davidson

Journal article  |  2020

Genomic rearrangements can modify gene function by altering transcript sequences, and have been shown to be drivers in both cancer..

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

CD DiNardo, IS Tiong, A Quaglieri, S MacRaild, S Loghavi, FC Brown, R Thijssen, G Pomilio, A Ivey, JM Salmon, C Glytsou, SA Fleming, Q Zhang, H Ma, KP Patel, SM Kornblau, Z Xu, CC Chua, Xufeng Chen, P Blombery, et al.

Journal article  |  2020  |  BLOOD

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for..